Cargando…

Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor

BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-α inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-α inhibitors. METHODS: Patients with TB detec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Keun Bum, Lee, Eun Young, Im, Jong Pil, Han, Sung Koo, Yim, Jae-Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604607/ https://www.ncbi.nlm.nih.gov/pubmed/23525649 http://dx.doi.org/10.3904/kjim.2013.28.2.174

Ejemplares similares

The Effect of Necrosis Inhibitor on Dextran Sulfate Sodium Induced Chronic Colitis Model in Mice
por: Kim, Dongwoo, et al.
Publicado: (2023)

Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy
por: Yoo, In Kyung, et al.
Publicado: (2014)

Unusual location of tuberculosis in the course of tumor necrosis factor α inhibitor therapy
por: Bielewicz-Zielińska, Agnieszka, et al.
Publicado: (2015)

Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
por: Sung, Yoon-Kyoung, et al.
Publicado: (2018)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection
por: Lee, Eun Hye, et al.
Publicado: (2017)

Bacteriologically Determined De Novo Tuberculosis during Tumor Necrosis Factor-α Inhibitor Therapy
por: Takahashi, Gen, et al.
Publicado: (2019)

The Interval Between Initiation of Anti-tuberculosis Treatment in Patients with Culture-positive Pulmonary Tuberculosis and Receipt of Drug-susceptibility Test Results
por: Joh, Joon-Sung, et al.
Publicado: (2007)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Erratum: Correction of Notes. Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Clinical Effects of Gemifloxacin on the Delay of Tuberculosis Treatment
por: Kim, Seo Yun, et al.
Publicado: (2013)

Follow-up Testing of Interferon-Gamma Release Assays Are Useful in Ankylosing Spondylitis Patients Receiving Anti-Tumor Necrosis Factor Alpha for Latent Tuberculosis Infection
por: Son, Chang-Nam, et al.
Publicado: (2014)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis
por: Lee, Sang-Oh
Publicado: (2013)

Changes in Diagnostic Methods for Pulmonary Tuberculosis between 2005 and 2013
por: Ahn, Bin, et al.
Publicado: (2015)

Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
por: Song, Joo Hye, et al.
Publicado: (2021)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis
por: Jun, Yu Kyung, et al.
Publicado: (2022)

Characteristics of Patients Who Visit the Emergency Department with Self-Inflicted Injury
por: Lee, Choung Ah, et al.
Publicado: (2012)

Impact of sputum gross appearance and volume on smear positivity of pulmonary tuberculosis: a prospective cohort study
por: Yoon, Soon Ho, et al.
Publicado: (2012)

Prevalence and Its Predictors of Extrapulmonary Involvement in Patients with Pulmonary Tuberculosis
por: Kim, Min Jae, et al.
Publicado: (2009)

Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy
por: Han, Sun Ae, et al.
Publicado: (2016)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018)

Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017
por: Katrak, Shereen S, et al.
Publicado: (2021)

Changes in histopathology and tumor necrosis factor-α levels in the hearts of rats following asphyxial cardiac arrest
por: Lee, Jung Hoon, et al.
Publicado: (2017)

Clinical Features of Patients on Home Oxygen Therapy Due to Chronic Respiratory Failure at One University Hospital
por: Kim, Kyoung Hee, et al.
Publicado: (2012)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
por: Kim, Seo Yun, et al.
Publicado: (2013)

Achievements in and Challenges of Tuberculosis Control in South Korea
por: Kim, Ji Han, et al.
Publicado: (2015)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Impact of outdoor air pollution on the incidence of tuberculosis in the Seoul metropolitan area, South Korea
por: Hwang, Seung-sik, et al.
Publicado: (2014)

Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome
por: Kim, Hae Rim, et al.
Publicado: (2013)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
por: Lee, Jang Wook, et al.
Publicado: (2016)

Short-term Analysis of the Residual Volume of an Eye Drop Following 23-Gauge Microincision Vitrectomy Surgery
por: Kang, Yong Koo, et al.
Publicado: (2017)

Clinical Characteristics of Pulmonary Embolism with Underlying Malignancy
por: Lee, Ji Eun, et al.
Publicado: (2010)

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
por: Oh, Gyu Man, et al.
Publicado: (2020)

Tumor necrosis factor‐α inhibitor‐induced follicular psoriasiform eruption
por: Goldberger, Tal, et al.
Publicado: (2022)

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice
por: Chen, Yi-Hsing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7n7ionfv28mi0eff98ev4ohh24